27 April 2021 | 08:46am
StockMarketWire.com - Clinical-stage drug development company ValiRx narrowed full-year losses after it cut back on R&D and administrative spending.
Pre-tax losses for the year through December amounted to £1.54 million, compared to year-on-year losses of £2.7 million.
The company said it had launched a new strategy and implemented structural changes to develop a risk-diversified approach to early-stage drug development .
A phase 1/2 clinical trial close out and reporting of lead asset VAL201 had demonstrated good safety and tolerability and early indications of efficacy. The launch of our new strategy has enabled us to start building connections with universities, institutions and medical research charities, chief executive Suzy Dilly said.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
/Global Epigenetics Drugs Market 2020: Growth, Emerging Trends And Forecast By Illumina, Inc., Merck Sharp & Dohme Corp, Qiagen; Abcam PLC,. Zymo research, Qiagen, CellCentric Ltd
Global Epigenetics Drugs Market 2020: Growth, Emerging Trends And Forecast By Illumina, Inc., Merck Sharp & Dohme Corp, Qiagen; Abcam PLC,. Zymo research, Qiagen, CellCentric Ltd
Global epigenetics drugs market is expected to gain market growth at a healthy CAGR 17.80% in the forecast period of 2020 to 2027 11
An all inclusive Epigenetics Drugs market report gives essential information, objective insights regarding international market trends and leads, competitor analysis, and much more. All the teams involved in building this market research report including consultants, market researchers, and data providers work hand-in-hand to generate more insightful data. Traditional research methodologies are supplemented with pioneering approaches to offer evidence-based insights via this market research repo
Search jobs 18-Dec-2020 Epigenetics Drugs Market Size, Share, Trends: Rapid Growth, Companies Profile, Key Features, Advancements, Technology development & Forecast 2027
Global Epigenetics Drugs Market Size, Share, Growth, Industry Trends and Forecast to 2025 is a comprehensive research that defines the vital growth factors, opportunities, and market segment of top players during the forecast period from 2020 to 2027. The report focuses on the overall consumption structure, development trends, sales models, and sales of top countries in the global Epigenetics Drugs market. The report offers a complete market outlook and development rate during the past, present, and the forecast period. It offers a concise study of well-known providers, market value, volume, price trends, competition, and development opportunities. The versatile and up-to-date information on the market is provided in this report. The study comprises a summary of imp